CG Oncology initiated with a Buy at Roth MKM

Roth MKM initiated coverage of CG Oncology with a Buy rating and $65 price target. The firm expects share momentum as cretostimogene approaches a BLA submission in BCG-unresponsive, high-risk non-muscle invasive bladder cancer, or HR-NMIBC, in the second half of 2025, adding that it views cretostimogene’s tolerability as “a major differentiator” that could help gain market share from competitors that have tolerability issues in this setting. The firm sees potential for $2B-plus in 2033 worldwide sales of creostimogene, the analyst added.